TargetMol

PIK-75 hydrochloride

Product Code:
 
TAR-T2287
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2287-5mg5mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2287-10mg10mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2287-1mL1 mL * 10 mM (in DMSO)£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2287-25mg25mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2287-50mg50mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2287-100mg100mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
PIK-75 Hydrochloride is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM in cell-free assays.
CAS:
372196-77-5
Formula:
C16H15BrClN5O4S
Molecular Weight:
488.74
Pathway:
DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling; Apoptosis
Purity:
0.98
SMILES:
Cl.CN(N=Cc1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O
Target:
Apoptosis; DNA-PK; PI3K

References

1. Zheng Z, et al. Mol Pharmacol. 2011, 80(4), 657-664. 2. WO/2003/072557, 09/04/2003 3. Moir LM, et al. J Pharmacol Exp Ther. 2011, 337(2), 557-566. 4. Jude JA, et al. Am J Respir Cell Mol Biol. 2012. doi:10.1165/rcmb.2012-0025OC. 5. Smirnova T, et al. Oncogene. 2012, 31(6), 706-715.